Scarica l'app Stockscreener
6.95
0.71%
-0.05
Arvinas Inc Borsa (ARVN) Ultime notizie
Bank of America Corp DE Has $2.47 Million Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Leerink Partnrs Estimates Arvinas' Q2 Earnings (NASDAQ:ARVN) - MarketBeat
H.C. Wainwright reaffirms buy rating on Arvinas stock after trial data - Investing.com Nigeria
Voloridge Investment Management LLC Buys Shares of 39,063 Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas (NASDAQ:ARVN) Shares Gap DownHere's Why - MarketBeat
Arvinas (NASDAQ:ARVN) Cut to "Hold" at Leerink Partnrs - MarketBeat
What Analysts Are Saying About Arvinas Stock - Benzinga
Transcript : Arvinas, Inc.Special Call - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, ... - Bluefield Daily Telegraph
Arvinas (ARVN) Poised for Milestone with VERITAC-2 Trial Data | - GuruFocus
ASCO: Positive Phase III results for Arvinas and Pfizer's vepdegestrant - The Pharma Letter
Arvinas (ARVN) Sees Downgrade from Leerink Partners | ARVN Stock News - GuruFocus
Arvinas (NASDAQ:ARVN) Earns Market Perform Rating from Leerink Partners - MarketBeat
SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Arvinas, Pfizer Report Breast Cancer Treatment Phase 3 Trial Results; Arvinas Shares Down Pre-Bell - marketscreener.com
Arvinas and Pfizer Announce Phase 3 Trial Results - TipRanks
Leerink cuts Arvinas stock rating post ASCO meeting By Investing.com - Investing.com Nigeria
Arvinas (ARVN) Faces Downgrade Amid Clinical Trial Results | ARV - GuruFocus
Arvinas (ARVN) Announces Promising Phase 3 Trial Results for Vep - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - WV News
Arvinas (NASDAQ:ARVN) Shares Up 7.9%Time to Buy? - MarketBeat
Pfizer-Arvinas breast cancer drug tops AstraZeneca’s in delaying progression - WTVB
Arvinas (NASDAQ:ARVN) Shares Down 4.7%What's Next? - MarketBeat
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression - Reuters
Pfizer and Arvinas Plan FDA Submission for Breast Cancer Drug - GuruFocus
Pfizer, Arvinas report positive breast cancer drug trial - breakingthenews.net
Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2 - Seeking Alpha
(ARVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer - Pfizer
Arvinas And Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival For Patients With Esr1-Mutant, Er+/Her2- Advanced Breast Cancer - marketscreener.com
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progre - GuruFocus
Is Trump Media Stock a Buy After $2.5 Billion Bitcoin Treasury Deal? - The Globe and Mail
Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect? - MSN
Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer - BioPharma Dive
Arvinas and Pfizer's Vepdegestrant Significantly Improves - GlobeNewswire
Here Are My Top 3 High-Yield Pipeline Stocks to Buy Now - The Globe and Mail
3 Dividend Stocks to Buy With $500 and Hold Forever - The Globe and Mail
Arvinas to Present at Jefferies Global Healthcare Conference - GlobeNewswire
Arvinas to Present at Jefferies Global Healthcare Conference | ARVN Stock News - GuruFocus
Protein Degradation Pioneer Arvinas Reveals Latest Progress at Major Jefferies Healthcare Conference - Stock Titan
Arvinas, Inc. (NASDAQ:ARVN) Shares Purchased by Two Sigma Advisers LP - MarketBeat
Analysts Set Arvinas, Inc. (NASDAQ:ARVN) Target Price at $20.92 - MarketBeat
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm - Yahoo Finance
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN) - Business Wire
Analysts Are Saying TJX Companies Is a Buy Despite Lackluster Quarterly Earnings. Are They Right? - The Globe and Mail
Prediction: 2 AI Stocks Will Be Worth More Than Apple Stock Before the End of 2026 - The Globe and Mail
3 Top High-Yield Dividend Stocks to Buy and Hold Through at Least the End of the Decade - The Globe and Mail
Costco (COST) Is About to Report Q3 Earnings. Here’s What to Expect - The Globe and Mail
USDJPY Faces An Intraday Corrective Recovery: Elliott Wave Intraday Analysis - The Globe and Mail
Arvinas’s SWOT analysis: stock outlook shifts amid clinical setbacks By Investing.com - Investing.com South Africa
Woodline Partners LP Boosts Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
0.00%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):